Petráš Marek, Oleár Vladimir, Molitorisová Milica, Dáňová Jana, Čelko Alexander M, Nováková Elena, Štefkovičová Mária, Krištúfková Zuzana, Malinová Jana, Lesná Ivana Králová
Preventive Medicine, Third Faculty of Medicine, Charles University in Prague, 100 00 Prague, Czech Republic.
Faculty of Healthcare, Alexander Dubček University of Trenčín, 911 50 Trenčín, Slovakia.
Vaccines (Basel). 2019 Oct 7;7(4):139. doi: 10.3390/vaccines7040139.
We assessed the long-term persistence of humoral immunity against diphtheria in adults with childhood vaccination and the immunogenicity of a booster dose considering demographic, behavioural and vaccinating factors. We conducted a trial in 200 healthy Slovak adults aged 24-65 years, immunised against diphtheria in childhood and against tetanus at regular 10-15 year intervals, and receiving a dose of a tetanus-diphtheria toxoid vaccine. The response was determined by ELISA antibody concentrations of paired sera before and at 4 weeks post-vaccination. A seroprotection rate of 21% (95% confidence interval, CI 15.6-27.3%) was found in adults up to 59 years since the last vaccination with seroprotective levels of antibodies against diphtheria ≥0.1 IU/mL and a geometric mean concentration of 0.05 IU/mL. Conversely, seropositive levels ≥0.01 IU/mL were observed in 98% of adults (95% CI 95-99.5%). Booster-induced seroprotection was achieved in 78% of adults (95% CI 71.6-83.5%) clearly depending on pre-booster antibody levels correlating with age and time since the last vaccination. Moreover, only 54.2% of smokers and 53.3% of patients on statins exhibited seroprotection. Booster vaccination against diphtheria was unable to confer seroprotection in all recipients of only childhood vaccination.
我们评估了在儿童期接种疫苗的成年人中对白喉体液免疫的长期持续性,以及考虑人口统计学、行为学和接种因素的加强剂量的免疫原性。我们对200名年龄在24至65岁之间的健康斯洛伐克成年人进行了一项试验,这些人在儿童期接种过白喉疫苗,并每隔10至15年定期接种破伤风疫苗,且接受了一剂破伤风 - 白喉类毒素疫苗。通过接种疫苗前和接种后4周配对血清的ELISA抗体浓度来确定反应。自上次接种以来,在59岁及以下的成年人中发现血清保护率为21%(95%置信区间,CI 15.6 - 27.3%),白喉抗体血清保护水平≥0.1 IU/mL,几何平均浓度为0.05 IU/mL。相反,在9